Endpoint Callout

SKYRIZI Met Its Primary Endpoints¹

INSPIRE Phase 3 Induction

Clinical Remission* at Week 12:

24% SKYRIZI 1200 mg IV (n=646; P<0.001) with a long text wrapped

8% Placebo (n=320)

COMMAND All Subjects Maintenance Population^†

Clinical Remission* at Week 52:

45% SKYRIZI 180 mg SC (n=179; P<0.001)

41% SKYRIZI 360 mg SC (n=186; P<0.001)

26% Placebo (Induction Responders^‡) (n=182)

^†Includes patients who responded to 1800 mg, 1200 mg, or 600 mg in the Phase 2b/3 induction study; 600 mg and 1800 mg are not FDA-approved induction doses.[ss]¹

Endpoint Callout

SKYRIZI Met Its Primary Endpoints1

Clinical Remission* at Week 12:

Clinical Remission* at Week 52:

SKYRIZI Met Its Primary Endpoints¹